A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery

Recruiting now · Not applicable

Conditions studied: Hemostasis, Hemostatic Techniques

In brief

The objective of this clinical investigation is to evaluate the safety and efficacy of ETHIZIA to control minimal, mild, or moderate soft tissue bleeding during open surgery when compared to SURGICEL Original in the percentage of cases achieving hemostasis at 3 minutes after product application, and without re-bleeding up to 10 minutes after application.

Key facts

Study ID

NCT06664788

Run by

Ethicon, Inc.

People needed

108

Starts

2025-04-16

Expected to finish

2026-09-28

Last updated by the study team

2026-07-31

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pre-operative
• Participant is scheduled to undergo an elective open, abdominal, retroperitoneal, pelvic, thoracic (non-cardiac) or extremity surgical procedure
• Participant is willing and able to give written informed consent for the clinical investigation participation
• Intra-operative
• Participant in whom the Investigator can identify and visualize a target bleeding site for which any applicable conventional means for hemostasis (e.g., suture, ligature, or cautery) are ineffective or impractical
• Target Bleeding Site is identified to originate from soft tissue, defined as organ bed, loose areolar tissue, fat, lymphatic tissue/lymph node beds, and muscle
• The choice is made to use a hemostatic agent to stop the bleeding, and there is the ability to apply pressure on the surface of the hemostatic agent to achieve hemostasis
• Participant has a Target Bleeding Site with a SBSS score of 1, 2, or 3 (e.g., reflecting minimal, mild, or moderate bleeding severities)

You may not qualify if…

• Pre-operative
• Participant is scheduled for another planned surgery within the follow-up period and the subsequent surgery would jeopardize the ETHIZIA or SURGICEL Original application
• Participant is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, but allowing exclusive use of acetylsalicylic acid
• Participant has an active or suspected infection at the bleeding site
• Participant is pregnant, planning on becoming pregnant, or actively breastfeeding during the 28-day follow-up period
• Intra-operative
• Target bleeding site is identified to originate from parenchymal organ tissue, cardiovascular (anastomotic or cardiovascular repair sites) tissue, or is in proximity to a foramina in bone, or areas of bony confine
• Target bleeding site is from a large defect in an artery or vein that requires vascular reconstruction with maintenance of vessel patency

Where it is running

• Keck Hospital of USC — Los Angeles, California, United States (enrolling)
• Washington University Barnes Jewish Hospital — St Louis, Missouri, United States (enrolling)
• Capital Health Medical Center - Hopewell — Pennington, New Jersey, United States (enrolling)
• New York Presbyterian - Weill Cornell Medical Ctr — New York, New York, United States (enrolling)
• UT Health East Texas EMS Air 1 — Tyler, Texas, United States (enrolling)
• Intermountain Medical Center — Murray, Utah, United States (enrolling)
• UMC Radboud — Nijmegen, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.